FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
78,12 -0,83 (-1,05%) Bitcoin EUR
58.211,64 +3.187,41 (+5,79%)
60 Degrees Pharmaceuticals, Inc. (SXTP)
| Chiusura precedente | 0,2321 |
| Aperto | 0,2300 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,2011 - 0,2300 |
| Intervallo di 52 settimane | 0,2011 - 8,6500 |
| Volume | |
| Media Volume | 262.059 |
| Capitalizzazione | 2,43M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,9900 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 1,30 |
GlobeNewswire60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases
TTCR Improvement Tafenoquine v Placebo Simulated survival curve of sustained 4-day recovery from acute COVID-19 symptoms in the subset of non-hospitalized high and low risk patients enrolled in NCT04533347 with at least two moderate COVID symptoms randomized to receive tafenoquine or placebo (post hoc endpoint). FDA advice to Company suggested execution of ACLR8-LR, a placebo-controlled Phase IIB study of tafenoquine in COVID-19 patients, may not be feasible in the U.S. Company will therefore fo
GlobeNewswire60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use of tafenoquine in treating COVID-19; Company plans to resubmit a revised IND later in 2023, pending a feasibility assessment60P has paused further study start-up preparations related to ACLR8-LR, decreasing the Company’s short-term burn rate60P will continue planned efforts to expand its malaria busi
- GlobeNewswire
60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Management investor presentation webcast available Monday 9/11, 7:00 AM ETAttendees may request 1 x 1 meetings with management at meetings@hcwco.com WASHINGTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals Inc. (“60P” or the “Company”) (Nasdaq: SXTP), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that CEO Dr. Geoff Dow and CFO Ty Miller will participate in the H.C. Wainwright 25th Annual Global Investment Conference Septemb
